Valeant, Shkreli Put Profits Above Patients, Congress SaysBy and
`$1 bn here we come,'' Martin Shkreli writes in e-mail
House oversight committee democrats release internal documents
Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG, both under congressional investigation over skyrocketing drug prices, were focused on making money before helping patients, members of Congress said internal documents obtained from the companies show.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.